EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY

João L.C. Borges, Marie C. Gelato, Alan D. Rogol, Mary Lee Vance, Robert M. Macleod, D. Lynn Loriaux, Jean Rivier, Robert M. Blizzard, Richard Furlanetto, William S. Evans, Donald L. Kaiser, George R. Merriam, Joachim Spiess, Wylie Vale, Michael O. Thorner

Research output: Contribution to journalArticlepeer-review

133 Scopus citations

Abstract

Human pancreatic tumour growth hormone releasing factor (hpGRF-40) 10 μg/kg was administered intravenously to 6 normal young men and 12 adult patients who had presented in childhood with growth hormone (GH) deficiency (7 patients had isolated GH deficiency, 4 had multiple anterior pituitary hormone deficiencies, and 1 had Hand-Schüller-Christian [HSC] disease). hpGRF-40 administration increased serum GH concentrations in all normal subjects and in 3 of 7 patients with isolated GH deficiency and in the 1 with HSC disease; however, the mean serum GH concentration in the patients who responded was less than that of the normal subjects. Somatomedin C concentrations were increased 24 h after a single dose of hpGRF-40 in 8 of 10 patients with GH deficiency. All subjects experienced flushing in response to hpGRF-40. A patient with isolated GH deficiency received O·33 μg/kg hpGRF-40 every 3 h for 5 days. Despite the modest increase in GH in response to a subsequent dose of 10 μg/kg hpGRF-40, serum somatomedin C levels increased within 12 h from 0·06 to 0·1 U/ml and peaked at 0·36 U/ml at 72 h; in addition the patient with HSC disease, treated with hpGRF-40 daily for 5 days, demonstrated an increase in somatomedin C from 0·4 to 0·58 U/ml. The increase after hpGRF-40 in serum GH levels in this patient and the similar or greater responses in 3 of 7 patients suggest that at least some of these patients may have hypothalamic GH-releasinghormone deficiency. hpGRF-40 may be useful in distinguishing pituitary disease from hypothalamic disease. After hpGRF-40 administration serum somatomedin C levels may increase without a change in serum immunoreactive GH concentrations. Further studies are needed to determine whether hpGRF-40 is useful in promoting linear growth in children with GH deficiency.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalThe Lancet
Volume322
Issue number8342
DOIs
StatePublished - Jul 16 1983

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY'. Together they form a unique fingerprint.

Cite this